These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9620221)

  • 1. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation.
    Voelcker G; Bielicki L; Hohorst HJ
    J Cancer Res Clin Oncol; 1997; 123(11-12):623-31. PubMed ID: 9620221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and transport of oxazaphosphorines and the clinical implications.
    Zhang J; Tian Q; Yung Chan S; Chuen Li S; Zhou S; Duan W; Zhu YZ
    Drug Metab Rev; 2005; 37(4):611-703. PubMed ID: 16393888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier.
    Voelcker G
    Anticancer Drugs; 2021 Jan; 32(1):61-65. PubMed ID: 32701559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enzymatic basis of cyclophosphamide specificity.
    Hohorst HJ; Bielicki L; Voelcker G
    Adv Enzyme Regul; 1986; 25():99-122. PubMed ID: 3028054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase alpha holoenzyme: first results with new thiazolidinyl- and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters.
    Hohorst HJ; Bielicki L; Müller K; Voelcker G
    J Cancer Res Clin Oncol; 1988; 114(3):309-11. PubMed ID: 3384844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Causes and possibilities to circumvent cyclophosphamide toxicity.
    Voelcker G
    Anticancer Drugs; 2020 Jul; 31(6):617-622. PubMed ID: 32044797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester.
    Voelcker G; Hohorst HJ
    J Cancer Res Clin Oncol; 1998; 124(6):297-300. PubMed ID: 9692835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM; Wodinsky I; Myles A
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of new oxazaphosphorine anticancer drugs.
    Liang J; Huang M; Duan W; Yu XQ; Zhou S
    Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased antitumour activity of mesyl-I-aldophosphamide-perhydrothiazine, in vivo but not in vitro, compared to I-aldophosphamide-perhydrothiazine.
    Voelcker G; Pfeiffer B; Schnee A; Hohorst H
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):74-8. PubMed ID: 10664245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of 17 beta-hydroxy-3-aza-A-homo-4 alpha-androsten-4-one-p-N, N-bis(2-chloroethyl)aminophenoxyacetate (NSC-620480) in P388 leukemia. Activity of steroidal lactams in Ehrlich tumor.
    Catsoulacos P; Pairas G
    Methods Find Exp Clin Pharmacol; 1990 Sep; 12(7):501-5. PubMed ID: 2087151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
    Peter G; Wagner T; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.
    Ramonas LM; Erickson LC; Ringsdorf H; Zaharko DS
    Cancer Res; 1980 Oct; 40(10):3704-8. PubMed ID: 7438053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.
    Voelcker G; Wagner T; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):415-22. PubMed ID: 1277216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P; van Putten LM
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis.
    Belfayol-Pisanté L; Guillevin L; Tod M; Fauvelle F
    Fundam Clin Pharmacol; 2000; 14(4):415-21. PubMed ID: 11030450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity, interstrand cross-links and DNA fragmentation induced by 'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard.
    Fleer R; Brendel M
    Chem Biol Interact; 1982 Mar; 39(1):1-15. PubMed ID: 7037214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies.
    Voelcker G; Wagner T; Wientzek C; Hohorst HJ
    Cancer; 1984 Sep; 54(6 Suppl):1179-86. PubMed ID: 6467149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antitumor properties of activated cyclophosphamide analogues.
    Borch RF; Canute GW
    J Med Chem; 1991 Oct; 34(10):3044-52. PubMed ID: 1920355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
    Sladek NE; Landkamer GJ
    Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.